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ABSTRACT
Thegrowth andmetastasis ofsolid tumors notonly dependsontheirability toescape from immunesurveillance butalsohingeson their
ability to invade the vasculature system as well as to induce the formation of new blood vessels. Gr-1
þCD11b
þ myeloid-derived
suppressor cells (MDSCs), overproduced in tumor-bearing hosts, contribute significantly to all these aspects. They also have a potential
role in the osteolysis associated with bone metastases. They are formidable partners in tumor metastasis.  2010 American Society for
Bone and Mineral Research.
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Introduction
M
etastasis is the cause of cancer mortality. The growth and
metastasis of solid tumors not only depend on their ability
to escape from immune surveillance but also hinge on their
ability to invade the vasculature system as well as to induce the
formation of new blood vessels. Thus tumor blood vessels are
promising therapeutic target in the treatment of neoplastic
diseases. The approval of bevacizumab, a humanized mono-
clonal antibody that recognizes and blocks vascular endothelial
growth factor A (VEGFA), by the US Food and Drud Adminis-
tration as a first-line therapy for metastatic colorectal cancer
validates the ideas that VEGF is a key mediator of tumor
angiogenesis and that blocking angiogenesis is an effective
strategy to treat human cancer.
(1–3)
The microenvironment of solid tumors contains regions of
poor oxygenation and high acidity. Growing evidence from
clinicalandexperimentalstudiespointstoafundamentalrolefor
hypoxia in metastatic progression. Prolonged hypoxia increases
genomic instability, genomic heterogeneity, and epigenetic
alteration and thus may act as a selective pressure for tumor cell
variants.
(4)
One of the responses of the tumor host to hypoxic conditions
is an inflammation reaction. This is regulated through hypoxia-
inducible factor 1a (HIF-1a) and NF-kB–mediated chemokine
and cytokine secretion,
(5) resulting in the infiltration of a variety
of host-derived inflammatory cells into tumor tissues.
(6) These
host cells create an environment that favors tumor progression.
They provide growth factors, proangiogenic factors, proteases,
and adhesion molecules that facilitate tumor cell proliferation,
angiogenesis, invasion, and metastasis.
(7,8) Of the chemokines
and chemokine receptors in inflammatory cell recruitment,
stromal-derived factor 1 (SDF-1 or CXCL12) is considered one of
the key regulators of hematopoietic stem and progenitor cell
trafficking between the peripheral circulation and targeted
tumor tissues. SDF-1 mediates its effects on chemotaxis through
its receptor, CXCR4, which is highly expressed on putative stem
and progenitor cells.
(7) Another chemokine, CXCL5, is signifi-
cantly elevated in response to deleted or diminished transform-
ing growth factor b (TGF-b) signaling in tumor epithelial cells.
This chemokine was implicated initially in the recruitment of
neutrophils in the inflamed lung. Recent studies showed that
CXCL5, signaling through the CXCR2 receptor, was responsible
for the recruitment of Gr-1
þCD11b
þ cells into the breast
carcinoma tumor microenvironment with deletion of TGF-b
signaling
(9) (Fig. 1).
Gr-1
RCD11b
R Myeloid-Derived Suppressor
Cells
Gr-1
þCD11b
þ cells or MDSCs are significantly overproduced in
the bone marrow and spleens of tumor-bearing mice. There are
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1701high numbers of these cells in peripheral blood of tumor hosts,
including cancer patients. MDSCs express CD11b, a marker for
myeloid cells of the macrophage lineage, and a marker for
granulocytes, Gr-1; thus they are called Gr-1
þCD11b
þ cells.
MDSCs have been demonstrated to be immune suppressive
since the 1980s. They inhibit natural killer (NK), B, and T cells
through the production of arginase and reactive oxygen species;
they also inhibit functional maturation of dendritic cells and
promote type II macrophage development and thus represent
one mechanism of tumor escape from immune system control
and compromise the efficacy of cancer immunotherapy.
(10,11)
The immune suppression by these cells can be both a systemic
effect on secondary lymphoid organs and a local effect within
the tumor microenvironment.
There are two major subpopulations of these cells: mono-
nuclear cells (precursors for macrophages) and low-density
polymorphonuclear cells (immature neutrophils). Both popula-
tions suppress antigen-specific T-cell responses, but through
distinct effector molecules and signaling pathways.
(12) Recently,
MDSCs were found to directly disrupt the binding of specific
peptide–major histocompatibility complex (pMHC) dimers to
CD8-expressing T cells through nitration of tyrosines in a T-cell
receptor (TCR)–CD8 complex. This process makes CD8-expres-
sing T cells unable to bind pMHC dimers and to respond to the
specific peptide, although they retain their ability to respond to
nonspecific stimulation.
(13)
Interestingly, MDSCs produce large quantities of TGF-b. TGF-b
is known to inhibit immune surveillance mechanisms in the
tumor host.
(14) Publications from different laboratories, including
our own, demonstrate that Gr-1
þCD11b
þ immature myeloid
cells are a major source for high levels of TGF-b in the tumor
host.
(9,15,16) This induction of TGF-b by myeloid cells plays a
greater role in suppressing the immune response than
production of TGF-b by the tumor itself because blocking
production by these myeloid cells abrogated the suppression,
even though the TGF-b production by the tumor itself was not
affected.
(15) TGF-b markedly and directly suppresses the
transcription of genes encoding multiple key proteins of the
cytotoxic program of CD8
þ cytotoxic T lymphocytes (CTLs) such
as perforin and granzymes, cytotoxins that act through the
granule exocytosis pathway.
(17) This inhibition of CD8
þ CTLs is
mediated by Gr-1CD11b myeloid cells through the production of
TGF-b. TGF-b also alters the polarization of the CD8
þ cells in
tumor-bearing mice, resulting in elevated interleukin 17 (IL-17),
which suppressed apoptosis of tumor cells.
(18) TGF-b, coordi-
nated with IL-21, induces CD4
þCD25
þ regulatory T cells that
counterbalance the effect of IL-6 that promotes proinflammatory
IL-17-producing T cells.
(19) In addition, TGF-b is responsible for
CD4
þCD25
þ regulatory T-cell inhibition of NK cell functions.
(20)
MDSCs in the Tumor Microenvironment:
More Than Immune Suppression
Despite the data defining the overproduction of MDSCs in tumor
hosts and their depressive effect on host immune surveillance, it
is not clear whether these cells infiltrate into the tumor
microenvironment and whether they have direct interactions
withtumorcells.If theydo,whatmolecularmechanismsmediate
their recruitment into the tumor microenvironment? We found
that MDSCs infiltrate into tumors and promote tumor angiogen-
esis by expressing high levels of matrix metalloproteinase 9
(MMP9) and by directly incorporating into tumor endothe-
lium.
(21) Furthermore, MDSCs produce large quantities of TGF-b
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Fig. 1. Formidable partners in tumor metastasis: MDSCs suppress host immune surveillance through the production of multiple immune suppressive
cytokines, including TGF-b, VEGF, and PGE2. MDSCs also infiltrate the tumor microenvironment and contribute to tumor vasculature formation. In
addition, these immature myeloid cells produce large quantities of TGF-b and a variety of MMPs that promote tumor invasion.
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They migrate to the invasive front of the tumors, facilitating
tumor cell invasion and metastasis
(9) (Fig. 1). Recently, MDSCs
have also been implicated in tumor refractoriness to anti-VEGF
treatment.
(22) Bv8 (prokineticin 2), expressed in the bone
marrow, modulates mobilization of CD11b
þGr-1
þ cells from
the bone marrow during tumor development and also promotes
angiogenesis locally.
(23) These studies suggest that tumor-
infiltrating bone marrow–derived MDSCs change the dynamics
in the primary tumor microenvironment and result in alterations
in the signaling cascade in tumor cells, promoting tumor cell
invasion and metastasis. This work points out the important
participation of host cells and strongly supports the ‘‘seed and
soil’’ theory.
Several lines of evidence make the contribution of Gr-
1
þCD11b
þ to tumor metastasis particularly interesting: (1) These
cells are overproduced in tumor hosts that include cancer
patients with a variety of tumors. (2) MDSCs are composed of
immaturemyeloidcellsattheearlystagesofdifferentiation.They
are different from terminally differentiated tumor-associated
macrophages (TAMs), identified as Mac-1 (CD11b) and F4/80
þ,
which have been shown to promote tumor progression and
metastasis through elevated CSF-1 production and enhanced
epidermal growth factor (EGF) signaling in cancer cells.
(24)
Similarities between TAMs and these immature myeloid cells
were noticed from profiling work,
(25) but differences between
the two populations also were evident. For example, myeloid
suppressor cells produce high levels of TGF-b1, whereas TGF-b1
expressioninTAMswasrestrictedtounstimulatedTAMsandwas
not increased further by M2-biasing cytokines.
(25) M2 refers to a
subclass of macrophages based on their preferential secretion of
TGF-b, IL-4, and IL-10 compared with M1 macrophages, which
are activated to produce nitrogen oxide, IL-12, interferon-g (IFN-
g). MDSCs are also different from two other cell types in the
tumor microenvironment—neutrophils and mast cells, which
express Gr-1 but not CD11b. (3) MDSCs interact with other host
immunecells,including T,B,andNK cells. These cellsmaydictate
to the tumor microenvironment that a shift from inflammation/
immune response to anti-inflammatory/immune-suppressive
responses (Th1/Th2-like cytokine shift) may be responsible in
the metastatic liver milieu, as reported previously.
(26) It is unclear
whether systemic immune suppression and direct participation
in tumor progression are two different properties or different
manifestations of the same process.
TGF-b, a Key Regulator in the Interplay of
Cancer Cells and Bone Marrow-Derived
Inflammatory Cells
In addition to the suppressive effect in the immune system, TGF-
b is also one of the important regulators in inflammatory
reactions that orchestrate the tumor microenvironment. TGF-b
affects the expression of chemokine and chemokine receptors
such as CXCL5, SDF-1, and CXCR4. TGF-b also mediates NF-kB
signaling, the master regulator of inflammation reaction. Tumor-
infiltrating RANKL (receptor activator of NF-kB ligand)–expres-
sing cells activate nuclear IKKa and inhibit the transcription of
tumor metastasis suppressor Maspin, thereby promoting tumor
metastasis.
(27) TGF-b1 negatively regulates NF-kB activation in
the gut through Smad7.
(28) Inflammation induced by Helico-
bacter pylori infection in SMAD3-deficient mice caused the
development of colon cancer.
(29) Furthermore, TGF-b crosstalks
with inflammatory pathways through the modulation of IL-1.
(30)
In addition to epithelial cells, TGF-b signaling in stromal cells has
significant effects on tumor development and growth. Loss of
the TGF-b type II receptors in fibroblasts promotes mammary
carcinoma growth and invasion through upregulation of TGF-a–,
macrophage-stimulating protein (MSP)– and hepatocyte growth
factor (HGF)–mediated signaling networks.
(31)
Recent work from our laboratory suggests that TGF-b is a key
regulator in the interplay of cancer cells and bone marrow–
derived MDSCs. Diminished TGF-b signaling in breast tumor cells
resulted in the recruitment of MDSCs to the invasive front. This is
regulated through increased CXCL5/CXCR2 and SDF-1/CXCR4
chemokine signals
(9) (Fig. 1). In turn, these myeloid cells produce
large quantities of MMPs and TGF-b1, thus promoting tumor
invasion and metastasis. Our observation is supported by a
recent publication in which C–C chemokine receptor type 1
(CCR1)–positive myeloid cells (CD34
þ) are shown to be recruited
to colon cancers with deletion of Smad4 and promote tumor
invasion.
(32) Indeed, inflammatory cells (positive for CD45 and
BM8, a pan-macrophage marker) have been observed in head-
and-neck tumors lacking TGF-b signaling.
(33) In TGF-b1-deficient
mice, inflammation causes precancerous lesions to progress to
colon cancer.
(34)
In the distant premetastatic lung, TGF-b is one of the factors
produced by tumor cells responsible for the production of the
chemoattractants S100A8 and S100A9, which attract Mac1
þ
myeloid cells.
(35) Through this mechanism, tumor cells also
activated mitogen-activated protein kinase (MAPK) p38 to
acquire migratory activity with pseudopodia for invasion
(invadopodia).
(35) In addition, TGF-b also induces angiopoietin-
like 4 expression in cancer cells that are about to enter the
circulation. This disrupts vascular endothelial cell-cell junctions,
increases the permeability of lung capillaries, and facilitates the
transendothelial passage of tumor cells. This mechanism seems
to be important for tumor cell retention in the lungs but not in
bone.
(36)
MDSCs and Bone Metastasis
Hematopoietic progenitors, or MDSCs, play an important role in
the progress of metastasis at any site and certainly in the bone
marrow.Therefore,theyarelikelyimportantintheprogressionof
multiple myeloma and other tumors that frequently metastasize
to bone, including breast cancer, prostate cancer, and lung
cancer. Since MDSCs have a cell surface phenotype that overlaps
with that of progenitors in the osteoclast lineage, this suggests
that they also may have a capacity to develop into osteoclasts at
this site. Our group has examined their role in the progression of
the osteolytic bone disease associated with multiple myeloma.
Myeloma bone disease is characterized by osteoclast activity
adjacent to myeloma deposits. Nothing is known of the origin of
osteoclasts in either patients or preclinical murine models of
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precursors are. However, it is clearly likely to be an issue of
importance. The molecular signals that pass between osteoclast
precursors and myeloma cells in the bone microenvironment are
likely critical to progression of the disease, raising the possibility
that myeloma cells may influence MDSC differentiation and/or
function.
We have studied this in the 5T model of myeloma. The 5T
model of myeloma was described originally by Radl and
colleagues.
(37,38) They found that 1 in 200 C57Bl mice of the
KaLwRij strain developed myeloma spontaneously and that the
myeloma cells can be passaged by tail vein injection from mouse
to mouse. This reproduces the human disease remarkably, with
all the regular characteristics of myeloma, including tumor
growth within the bone marrow and the development of an
osteolytic bone disease. In this murine model, MDSCs were
increased in the bone marrow and spleen of myeloma-bearing
mice and correlated with progression of the disease.
(39)
Furthermore, MDSCs isolated from mice with myeloma had a
greater capacity to form osteoclasts than MDSCs from control
mice.
(39)MDSCswereisolatedfromlacZ
þmicebearingmyeloma.
Following coinoculation of these lacZ
þ MDSCs with myeloma
cells into recipient mice, cells positive for both lacZ and TRACP
were observed on the bone surface, demonstrating the MDSCs
have the capacity to differentiate into osteoclasts in vivo.
(39,40)
What did this mean? It means that this population of MDSCs that
are mobilized in vivo during initiation of the disease has multiple
potentials, one of which is to progress down the osteoclast
lineage to form mature bone-resorbing osteoclasts (Fig. 2).
Future directions of research should be aimed at identifying the
mechanisms by which myeloma cells induce these MDSCs to
formcellsofandtodifferentiatedowntheosteoclastlineageand
to clarify the molecular mechanism by which they influence and
possibly control myeloma cell function.
Myeloma serves as a potential paradigm for similar events
occurring in solid tumors that metastasize to bone. In these
situations, it is possible that the molecular mediators may be
different, but the general principles may remain the same. In
support of this, an increase in the proportion of granulocytic
myeloid-derived suppressor cells, defined as CD11b
þGR-1
þLy-
C6
 , was demonstrated in the long bones of a syngeneic mouse
model of breast cancer bone metastasis.
(41)
If these cells are so important to the skeletal complications
associated with cancer, then one question is whether depletion
of MDSCs affects tumor progression. There are potential
mechanisms by which this could be achieved, for example, by
liposome-mediated clodronate or other biosphonates, and it
would be interesting to see the efficacy of these approaches
when usedinthismanner. Bisphosphonates areinclinical usefor
the treatment of myeloma bone disease, and their effects on
mature osteoclasts are well studied. However, little is known of
their effects, if any, on osteoclast precursors such as MDSCs.
Melani and colleagues demonstrated that zoledronate
decreased the expansion of MDSCs associated with tumor-
bearing mice.
(42) This was mediated through inhibition of MMP-
9. Our own studies have demonstrated that bisphosphonate
treatment of myeloma-bearing mice results in a decrease in the
proportion of MDSCs.
(43) Isolation of these MDSCs from
myeloma-bearing mice treated with zoledronate confirmed a
reduction in their ability to form osteoclasts compared with
untreated myeloma-bearing mice. No evidence of inhibition of
protein prenylation was detected in MDSCs isolated from
myeloma-bearing mice treated with zoledronate, suggesting
that this effect of bisphosphonates on MDSCs is indirect and
independent of the characteristic inhibition of protein prenyla-
tion in mature osteoclasts.
Summary
MDSCs are a heterogeneous population of cells that are
enhanced in tumor-bearing hosts and appear to play a
Fig. 2. Potential role of MDSCs in myeloma bone disease. MDSCs are known to have the capacity to differentiate into neutrophils, dendritic cells, and
endothelial cells. We propose that myeloma cells may stimulate MDSCs to differentiate into osteoclasts and contribute to the osteolytic bone disease.
1704 Journal of Bone and Mineral Research YANG ET AL.number of roles in immune suppression and metastasis. It is
exciting to speculate that these cells may have a distinct role
in bone metastases, related not only to their immune
suppressive properties but also to their potential to contribute
to osteoclastogenesis and the subsequent destructive osteo-
lytic bone disease. Future studies to elucidate their specific
role in osteolytic bone disease not only will increase our
understanding of the pathophysiology of cancer-induced bone
disease but also may reveal novel therapeutic targets for the
treatment of this destructive characteristic feature of bone
metastases.
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